No Data
Wuhan Easy Diagnosis Biomedicine (002932.SZ) has repurchased 5.05% of its shares, costing approximately 0.224 billion yuan.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that, as of November 29, 2024, the company has cumulatively completed a total of...
Matilda Biotech: Report for the third quarter of 2024
wuhan easy diagnosis biomedicine (002932.SZ) released its performance for the first three quarters, with a net income of 80.9384 million yuan, a year-on-year decrease of 44.30%.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Wuhan Easy Diagnosis Biomedicine (002932.SZ): net income for the first three quarters was 80.9384 million yuan, a year-on-year decrease of 44.30%.
Gelonghui on October 30th: wuhan easy diagnosis biomedicine (002932.SZ) announced the third quarter report for 2024, with the company's revenue of 0.226 billion yuan in the first three quarters, a year-on-year decrease of 63.95%; net income attributable to shareholders of the listed company was 80.9384 million yuan, a year-on-year decrease of 44.30%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -39.0766 million yuan; basic earnings per share was 0.35 yuan.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): In 2024, the mid-term equity distribution is 0.30 yuan per share, ex-dividend date is October 17th.
Guolonghui October 10th ¦ wuhan easy diagnosis biomedicine (002932.SZ) announced that the company's 2024 interim shareholder distribution plan is: based on the existing total share capital of 232,520,957 shares, excluding the repurchased 9,547,867 shares, the share capital after the repurchase is 222,973,090 shares as the base, distributing 0.30 RMB cash per 10 shares to all shareholders. The record date for this equity distribution is October 16, 2024, and the ex-rights and ex-dividend date is October 17, 2024.
wuhan easy diagnosis biomedicine (002932.SZ): has repurchased 3.61% of the shares.
On September 2nd, Gelonghui announced that as of August 31st, 2024, Wuhan Easy Diagnosis Biomedicine (002932.SZ) repurchased 8,398,718 shares of the company's stock through a repurchase dedicated securities account through centralized bidding, accounting for 3.61% of the company's total share capital; The highest fill price for repurchased shares was RMB 20.98 per share, and the lowest fill price was RMB 16.35 per share, with a total fill amount of RMB 1.64 billion (excluding trading fees).
